Coverage
Filings
| Filing | Date |
|---|---|
| GSK publishes Annual Report 2024 | 27 Feb 2025 |
| Transaction in Own Shares | 26 Feb 2025 |
| Director/PDMR Shareholding | 26 Feb 2025 |
| Transaction in Own Shares | 25 Feb 2025 |
| GSK plc commences share buyback programme | 24 Feb 2025 |
| GSK completes acquisition of IDRx, Inc. | 24 Feb 2025 |
| Director/PDMR Shareholding | 21 Feb 2025 |
| Director/PDMR Shareholding | 21 Feb 2025 |
GSK said Monday it has appointed Chief Commercial Officer Luke Miels as its next chief executive, succeeding Dame Emma Walmsley.
GSK PLC announced plans to invest $30 billion in the United States over the next five years to boost its research, development, and manufacturing capabilities.
GSK said on Monday that the U.S. Food and Drug Administration has accepted for review its application to expand the use of its respiratory syncytial virus vaccine, Arexvy, to at-risk adults aged 18 to 49.
| 21 Feb 2025 |
| Director/PDMR Shareholding | 21 Feb 2025 |
| Director/PDMR Shareholding | 21 Feb 2025 |
| Director/PDMR Shareholding | 21 Feb 2025 |